RxDoctor Payments Data

Ashley Paul

Neurology · Baltimore, MDNPI 1902250335

Payments from drug & device makers

$33,362in general payments, 2019–2025

Across 49 payments — averaging $680.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Boston Scientific$10K
  • Acadia Pharmaceuticals Inc$864
  • Neurocrine Biosciences, Inc.$740
  • Sanofi$158
  • Biogen$90
  • plus $221 from 3 others

What the payments were for

  • Grants$30,00090%
  • Travel & lodging$9893%
  • Food & beverage$2,2277%
  • Education$1460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,362 in reported general payments places this provider in the 80th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$49,488
Medicare patients
162
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa54$141,698
NuplazidPimavanserin Tartrate13$65,842
NeuproRotigotine12$24,198
GocovriAmantadine Hcl12$20,672
Carbidopa-LevodopaCarbidopa/Levodopa144$7,701
Carbidopa-Levodopa ErCarbidopa/Levodopa71$4,192
Rivastigmine13$2,902
AmantadineAmantadine Hcl27$1,817
Pregabalin24$1,213
RivastigmineRivastigmine Tartrate12$1,178
Zonisamide23$1,075
Quetiapine Fumarate14$242
Donepezil Hcl29$228
Mirtazapine11$187
Clonazepam19$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$864$65,84213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →